Product Information
LAMOTRIGINE 150 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $0.0695 per EA under NDC 72888002760. Its NADAC has been published 193 times since Jan 25, 2023.
FDA first approved this application on Jan 27, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888002760
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LAMOTRIGINEApproval Type
Generic (ANDA)
FDA Application
ANDA078625FDA Approved
1/27/2009
TE Code
AB
On Market Since
10/29/2021
Pharmacological Classes
Price Statistics
The NADAC for LAMOTRIGINE 150 MG TABLET has been published 193 times since Jan 25, 2023, and over the history we have for it it has declined 2.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0695 per EA |
|---|---|
| All-time high | $0.0756 (Mar 15, 2023) |
| All-time low | $0.0540 (Nov 20, 2024) |
| 52-week high | $0.0728 |
| 52-week low | $0.0630 |
| Median price | $0.0686 |
| Average price | $0.0679 |
| Largest weekly change | +25.4% (Aug 21, 2024) |
| Weeks tracked | 193 |
| Tracking since | Jan 25, 2023 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lamotrigine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMOTRIGINE 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMOTRIGINE 150 MG TABLET, manufactured by Advagen Pharma Ltd., is $0.0695 per EA (NDC 72888002760), effective Sep 30, 2026.
How has the price of LAMOTRIGINE 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMOTRIGINE 150 MG TABLET has declined 2.6%. It has been tracked across 193 weekly CMS publications since Jan 25, 2023.
What are the highest and lowest recorded NADAC prices for LAMOTRIGINE 150 MG TABLET?
Since Jan 25, 2023, the NADAC for LAMOTRIGINE 150 MG TABLET has ranged from a low of $0.0540 (Nov 20, 2024) to a high of $0.0756 (Mar 15, 2023), with a median of $0.0686 per EA.
Are there cheaper alternatives to LAMOTRIGINE 150 MG TABLET?
11 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LAMOTRIGINE 150 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LAMOTRIGINE 150 MG TABLET?
LAMOTRIGINE 150 MG TABLET (NDC 72888002760) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.